- All sections
- C - Chemistrymetallurgy
- C07D - Heterocyclic compounds
- C07D 207/12 - Oxygen or sulfur atoms
Patent holdings for IPC class C07D 207/12
Total number of patents in this class: 707
10-year publication summary
|
43
|
66
|
44
|
53
|
64
|
48
|
36
|
48
|
38
|
23
|
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Sanofi | 4301 |
24 |
| Journey Medical Corporation | 99 |
20 |
| Bristol-myers Squibb Company | 4742 |
19 |
| Novartis AG | 10262 |
18 |
| Takeda Pharmaceutical Company Limited | 2712 |
17 |
| Bodor Laboratories, Inc. | 59 |
13 |
| Merck Sharp & Dohme LLC | 3734 |
9 |
| Boehringer Ingelheim International GmbH | 4493 |
8 |
| Integrative Research Laboratories Sweden AB | 37 |
8 |
| F. Hoffmann-La Roche AG | 7837 |
7 |
| Chiesi Farmaceutici S.p.A. | 959 |
7 |
| Recurium IP Holdings, LLC | 125 |
7 |
| Hoffmann-La Roche Inc. | 3793 |
6 |
| Alkermes Pharma Ireland Limited | 254 |
6 |
| Alnylam Pharmaceuticals, Inc. | 1179 |
6 |
| Astellas Pharma Inc. | 1044 |
6 |
| Cayman Chemical Company, Incorporated | 64 |
6 |
| Tetraphase Pharmaceuticals, Inc. | 52 |
6 |
| Correvio International Sàrl | 16 |
6 |
| Gen1e Lifesciences Inc. | 31 |
6 |
| Other owners | 502 |